Eledon Pharmaceuticals, Inc.

ELDN

US28617K1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
2.31 ^USD	-3.75%		-4.15%	+28.33%

May. 07	Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	CI
May. 06	Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding	CI

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

September 04, 2020 at 04:27 pm EDT

Novus Therapeutics, Inc. accepted the resignation of Gregory Flesher as the Company's Chief Executive Officer and a member of the Board.

Latest news about Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	May. 07	CI
Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding	May. 05	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours	Mar. 25	MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	Mar. 25	CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care	Mar. 21	MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human	Mar. 21	MT
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Eledon Pharmaceuticals, Inc. - Special Call	Nov. 02
Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	Nov. 02	CI
Eledon Pharmaceuticals Names Eliezer Katz Chief Medical Officer	23-10-23	MT
Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer	23-10-23	CI
Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors	23-10-02	CI
Noble Capital Initiates Coverage on Eledon Pharmaceuticals with Outperform Rating, $10 Price Target	23-09-27	MT
Eledon's Investigational Antibody Used in Treatment Regimen After Pig-to-Human Heart Transplant	23-09-25	MT
Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023	23-09-12	CI
Eledon Pharmaceuticals, Inc. Announces Publication of Study Evaluating Tegoprubart as an Immunomodulatory Monotherapy in Nonhuman Primate Kidney and Islet Allotransplants	23-09-06	CI
Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation	23-09-05	CI
Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation	23-08-16	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000E Index	23-06-23	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Index	23-06-23	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000E Value Index	23-06-23	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Index	23-06-23	CI

Chart Eledon Pharmaceuticals, Inc.

Duration

Period

More charts

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Companyâs lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Sector

Biotechnology & Medical Research

Calendar

2024-06-03 - American Transplant Congress - Poster No: 6647

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.31 USD

Average target price

14 USD

Spread / Average Target

+506.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELEDON PHARMACEUTICALS, INC.	+28.33%	57.32M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Biotechnology & Medical Research

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

Latest news about Eledon Pharmaceuticals, Inc.

Chart Eledon Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs